Safety and Efficacy of Blinatumomab in Combination with a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-Positive Leukemia
Conclusions The combination of blinatumomab with TKI is safe and effective in patients with relapsed/refractory Ph+ disease. Prospective studies are warranted.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Actemra | Acute Leukemia | Acute Lymphoblastic Leukemia | Cancer & Oncology | Cardiology | Cardiovascular | Chemotherapy | Chronic Leukemia | Chronic Myeloid Leukaemia | Heart | Hematology | Leukemia | Lymphoma | Myeloma | Stem Cell Therapy | Stem Cells | Study | Transplants